Atara Biotherapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Atara Biotherapeutics

01/05/2023 12:58

* Atara Biotherapeutics Inc  ATRA.OQ   ATRA.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 3
(estimated). 
    * The Thousand Oaks California-based  company is expected to
report  a 319.4% increase in revenue to $30.678 million from
$7.31 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Atara
Biotherapeutics Inc
is for a loss of 39 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $25​, above​ its last closing price
of $2.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.49       -0.51      -0.72     Missed  -41.8
 Sep. 30 2022  -0.77       -0.78      -0.82     Missed  -4.5
 Jun. 30 2022  -0.91       -0.93      -0.31     Beat    66.5​
 Mar. 31 2022  -0.99       -0.98      -0.87     Beat    11.2
 ​​Dec.        -0.67       -0.69      -0.96     Missed  -40
 31 2021                                                
 Sep. 30 2021  -0.93       -0.94      -0.90     Beat    4​
 Jun. 30 2021  -0.87       -0.89      -0.91     Missed  -2.1
 Mar. 31 2021  -0.90       -0.92      -0.86     Beat    6.6
 This summary was machine generated May 1 at 11:58 GMT.  All
figures in US dollars  unless otherwise stated